For this reason, we assessed the relationship between PSA level at sLND, 68Ga‐PSMA PET scan feature and oncologic outcomes with the aim of identifying the patients who have benefited the most from sLND and thus optimize the timing for 68Ga‐PSMA PET in biochemical recurrent prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.